Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Inclusion Criteria

• Histological confirmation of non-clear cell renal cancer (including chromophilic [papillary], chromophobic, oncocytic, sarcomatoid, collecting duct [Bellini's duct]), translocation-type carcinoma or medullary renal cell carcinoma
• Up to one prior treatment for metastatic non clear cell carcinoma is allowed prior to registration as long as the agent used to treat was not pazopanib
• Measurable or non-measurable metastatic disease
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
• Absolute neutrophil count (ANC) >= 1500
• Platelets (PLT) >= 100,000
• Hemoglobin (HgB) > 9.0 g/dL; NOTE: subjects may not have had a transfusion within 7 days of registration
• Total bilirubin = 1, then a 24-hour urine protein must be assessed; subjects must have a 24-hour urine protein value = 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value > 40 mIU/mL and an estradiol value = 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT
• Childbearing potential, including any female who has had a negative serum pregnancy test, = = 140 mmHg or diastolic blood pressure [DBP] of >= 90mmHg)
• Symptomatic congestive heart failure as defined by the New York Heart Association (NYHA); does not exclude class III congestive heart failure (CHF)
• Previously treated with therapies that are known to negatively impact cardiac function (e.g. prior treatment with anthracyclines)
• Unstable angina pectoris
• Cardiac arrhythmia
• Evidence of active bleeding or bleeding diathesis
• Psychiatric illness/social situations that would limit compliance with study requirements
• Or any other serious uncontrolled medical disorders in the opinion of the investigator
• History of cerebrovascular accident including transient ischemic attack (TIA), myocardial infarction, pulmonary embolism or untreated deep venous thrombosis (DVT), coronary artery bypass graft surgery within 6 months prior to registration; Note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible
• Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
• Other active malignancy = 480 msecs using Bazett's formula
• Receiving any medications or substances with risk of torsades de pointes; Note: medications or substances on the list "Drugs with Risk of Torsades de Pointes" are prohibited; medications or substances on the list "Drugs with Possible or Conditional Risk of Torsades de Pointes" may be used while on study with extreme caution and careful monitoring
• Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels and/or hemoptysis in excess of 2.5 mL (or one half teaspoon) =< 8 weeks of registration
• Treatment with any of the following anti-cancer therapies: radiation therapy, surgery or tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy =< 14 days prior to registration
• Prior autologous or allogeneic organ or tissue transplantation
• Elective or planned major surgery to be performed during the course of the trial
• Receiving any medications or substances that are strong or moderate inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4); use of the strong or moderate inhibitors are prohibited =< 7 days prior to registration
• Receiving any medications or substances that are inducers of CYP3A4; use of inducers are prohibited =< 7 days prior to registration